Breaking News
Get 50% Off 0
🤔 Tesla Q2 earnings report - is now the right time to buy?
Explore Tesla Data
Close

Medlive Technology Co Ltd (2192)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
14.66 +0.48    +3.39%
08:19:45 - Delayed Data. Currency in HKD
Type:  Equity
Market:  Hong Kong
ISIN:  KYG5961B1041 
  • Volume: 1,713,864
  • Bid/Ask: 14.62 / 14.66
  • Day's Range: 14.14 - 14.82
Medlive Technology Co 14.66 +0.48 +3.39%

Medlive Technology Co Ltd Company Profile

 
Get an in-depth profile of Medlive Technology Co Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryMedia & Publishing
SectorConsumer Cyclicals
Employees

747

Equity Type

ORD

Medlive Technology Co., Ltd. operates an online professional physician platform in Mainland China and internationally. The company’s precision marketing and corporate solution provides digital marketing, digital detailing, digital marketing consultation, digital content creation, application software development, and other relevant services. Its medical knowledge solution offers medical education and clinical decision support, including licensing software to physicians and other registered users, such as other healthcare professionals and pharmaceutical companies. The company’s intelligent patient management solutions include single disease management services, such as disease knowledge dissemination and treatment compliance monitoring; patient education services comprising content development, application software development, and other related services; and chronic disease management services for Parkinson's lymphoma, stroke and diabetes, breast cancer, lung cancer, and ovarian cancer. In addition, it is involved in the provision of research and development services; provision of internet hospital services; provision of publication and planning services for medicine guidelines and medical consensus; organizing medical exhibition conferences; provision of medical services; and provision of research services to pharmaceutical companies. The company was formerly known as Kingyee Co., Limited and changed its name to Medlive Technology Co., Ltd. in 2021. The company was founded in 1996 and is headquartered in Beijing, China.

Contact Information

Address Yimaitong Mansion Huangqu East Road No. 5
Courtyard Building 4 Chaoyang District Beijing,
China
Phone -
Fax -

Top Executives

Name Age Since Title
Lijun Tian 50 2013 VP, Deputy Head of Medical Information Science Research Unit & Executive Director
Liping Tian 57 2013 Chairwoman & CEO
Richard L. Yeh 56 2021 Independent Non-Executive Director
Xin Zhou 44 2018 VP & Executive Director
Lixin Tian 55 2013 President, Head of Medical Information Science Research Unit & Executive Director
Jun Ma 69 2021 Independent Non-Executive Director
Kazutaka Kanairo 47 2023 Non-Executive Director
Shan Wang 50 2021 Independent Non-Executive Director
Eiji Tsuchiya 61 2013 Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

2192 Comments

Write your thoughts about Medlive Technology Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email